BUZZ-Sarepta gains after Q3 revenue beat

reuters11-07

** Shares of therapy maker Sarepta Therapeutics SRPT.O rise 3.91% to $132.97 premarket

** Company reports Q3 revenue of $467.2 mln, beating analysts' estimate of $409.30 mln - LSEG data

** Q3 net product revenue for Elevidys, its gene therapy for Duchenne muscular dystrophy, at $181 mln

** Duchenne muscular dystrophy is a condition that causes skeletal and heart muscle weakness that quickly gets worse with time

** Company says it will discontinue development of therapy SRP-5051 that was being studied to treat patients with a type of Duchenne muscular dystrophy

** In a small number of patients, company saw persistent hypomagnesemia-a condition where the level of magnesium in the blood is below normal-despite treatment discontinuation

** Up to last close, stock up ~32% YTD

(Reporting by Sriparna Roy in Bengaluru)

((Sriparna.Roy@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481900256?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-07 21:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481900256","market":"us","top_or_hot":-1,"title":"BUZZ-Sarepta gains after Q3 revenue beat","media":"reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Sarepta gains after Q3 revenue beat </title></head><body><p>** Shares of therapy maker <a href=\"https://laohu8.com/S/SRPT\">Sarepta Therapeutics</a> <span>SRPT.O</span> rise 3.91% to $132.97 premarket</p><p>** Company <span>reports</span> Q3 revenue of $467.2 mln, beating analysts' estimate of $409.30 mln - LSEG data</p><p>** Q3 net product revenue for <span>Elevidys</span>, its gene therapy for Duchenne muscular dystrophy, at $181 mln</p><p>** Duchenne muscular dystrophy is a condition that causes skeletal and heart muscle weakness that quickly gets worse with time</p><p>** Company says it will discontinue development of therapy SRP-5051 that was being studied to treat patients with a type of Duchenne muscular dystrophy</p><p>** In a small number of patients, company saw persistent hypomagnesemia-a condition where the level of magnesium in the blood is below normal-despite treatment discontinuation</p><p>** Up to last close, stock up ~32% YTD</p><p> (Reporting by Sriparna Roy in Bengaluru)</p><p> ((Sriparna.Roy@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Sarepta gains after Q3 revenue beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Sarepta gains after Q3 revenue beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-07 21:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nL4N3ME1KM:1><strong>reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BUZZ-Sarepta gains after Q3 revenue beat ** Shares of therapy maker Sarepta Therapeutics SRPT.O rise 3.91% to $132.97 premarket** Company reports Q3 revenue of $467.2 mln, beating analysts' estimate ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nL4N3ME1KM:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SRPT","symbol_name":"Sarepta Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nL4N3ME1KM:1","article_id":"2481900256","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481900256","pubTimestamp":1730987656,"sourceInfo":null,"weMediaInfo":{"media_name":"reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Sarepta gains after Q3 revenue beat ** Shares of therapy maker Sarepta Therapeutics SRPT.O rise 3.91% to $132.97 premarket** Company reports Q3 revenue of $467.2 mln, beating analysts' estimate of $409.30 mln - LSEG data** Q3 net product revenue for Elevidys, its gene therapy for Duchenne muscular dystrophy, at $181 mln** Duchenne muscular dystrophy is a condition that causes skeletal and heart muscle weakness that quickly gets worse with time** Company says it will discontinue development of therapy SRP-5051 that was being studied to treat patients with a type of Duchenne muscular dystrophy** In a small number of patients, company saw persistent hypomagnesemia-a condition where the level of magnesium in the blood is below normal-despite treatment discontinuation** Up to last close, stock up ~32% YTD  ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SRPT":"Sarepta Therapeutics"},"translate_title":"BUZZ-Sarepta在第三季度收入超出预期后上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SRPT":0.9},"content_text":"BUZZ-Sarepta gains after Q3 revenue beat ** Shares of therapy maker Sarepta Therapeutics SRPT.O rise 3.91% to $132.97 premarket** Company reports Q3 revenue of $467.2 mln, beating analysts' estimate of $409.30 mln - LSEG data** Q3 net product revenue for Elevidys, its gene therapy for Duchenne muscular dystrophy, at $181 mln** Duchenne muscular dystrophy is a condition that causes skeletal and heart muscle weakness that quickly gets worse with time** Company says it will discontinue development of therapy SRP-5051 that was being studied to treat patients with a type of Duchenne muscular dystrophy** In a small number of patients, company saw persistent hypomagnesemia-a condition where the level of magnesium in the blood is below normal-despite treatment discontinuation** Up to last close, stock up ~32% YTD (Reporting by Sriparna Roy in Bengaluru) ((Sriparna.Roy@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"Business Data","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481900256"}